CVS News Alert CVS Corp (CVS) 95.10 01/03/2015 13:37:16

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
CVS Corp (CVS) 95.10 $CVS

My Dividend Portfolio: 2014 Q4 Update
Integrator - at Seeking Alpha - Sat Jan 03, 7:18AM CST

BDX: 139.86 (+0.70), GE: 25.06 (-0.21), LMT: 193.31 (+0.74), CLX: 103.87 (-0.34), HSY: 103.71 (-0.22), NKE: 95.03 (-1.12), WBK: 26.82 (-0.08), PEP: 94.44 (-0.12), SBUX: 81.44 (-0.61), CME: 88.14 (-0.51), JNJ: 104.52 (-0.05), COST: 141.61 (-0.14), BP: 38.12 (unch), MSFT: 46.76 (+0.31), CSCO: 27.61 (-0.21), YUM: 72.35 (-0.50), KO: 42.14 (-0.08), CHD: 79.09 (+0.28), COP: 68.92 (-0.14), AMGN: 159.89 (+0.60), DIS: 93.75 (-0.44), ADP: 83.29 (-0.08), CVS: 95.10 (-1.21), PG: 90.44 (-0.65), VZ: 46.96 (+0.18), CL: 69.04 (-0.15)

Walgreen Closes Alliance Boots Buyout; Renames Company - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 12:40PM CST
Walgreens Boots Alliance Inc., the first global pharmacy-led health and wellbeing enterprise, will start trading on the Nasdaq under the ticker symbol "WBA".
ABMD: 37.31 (-0.75), WBA: 76.00 (-0.20), CVS: 95.10 (-1.21), RAD: 7.63 (+0.11)

CVS Caremark (CVS) Crosses Pivot Point Support at $95.72
Comtex SmarTrend(R) - Fri Jan 02, 10:13AM CST
Shares of CVS Caremark (NYSE:CVS) opened today below their pivot of $96.79 and have already reached the first level of support at $95.72. Investors may be interested in a cross of the next downside pivot targets of $95.12 and $93.45.
CVS: 95.10 (-1.21)

Key Rite Aid sales metric climbs 5.3 percent in December
By The Associated Press - AP - Fri Jan 02, 9:01AM CST
Rite Aid's revenue from established stores climbed more than 5 percent last month, as growing prescription totals countered a hit from cheaper generic drugs for the nation's third-largest drugstore chain.
CVS: 95.10 (-1.21), RAD: 7.63 (+0.11)

After Yesterday's Decline of 1.25%, CVS Caremark Offers Investors Better Value
Comtex SmarTrend(R) - Wed Dec 31, 3:55PM CST
CVS Caremark (NYSE:CVS) traded in a range yesterday that spanned from a low of $96.20 to a high of $97.87. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $97.06 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CVS: 95.10 (-1.21)

CVS Caremark Set to Possibly Rebound After Yesterday's Selloff of 1.25%
Comtex SmarTrend(R) - Wed Dec 31, 3:55PM CST
CVS Caremark (NYSE:CVS) traded in a range yesterday that spanned from a low of $96.20 to a high of $97.87. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $97.06 on volume of 3.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CVS: 95.10 (-1.21)

Rite Aid (RAD) Looks Promising; Have You Invested in It Yet? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 3:25PM CST
Rite Aid Corp. (RAD) is scoring high on the favorability radar, backed by a splendid stock performance all through 2014, having witnessed 49.4% growth year to date.
NPD: 1.54 (-0.04), CVS: 95.10 (-1.21), WMT: 85.90 (+0.02), RAD: 7.63 (+0.11)

Rite Aid, Nokia and Sirius XM, 3 Stocks Under $10 to Buy in 2015
at The Street - Wed Dec 31, 1:28PM CST
Investors looking for growth and value may find it in Rite Aid, Nokia and Sirius XM -- stocks trading under $10.
CVS: 95.10 (-1.21), MSFT: 46.76 (+0.31), WAG: 76.05 (-0.49), SIRI: 3.47 (-0.03), NOK: 8.01 (+0.15), RAD: 7.63 (+0.11)

24.1% Return Seen to Date on SmarTrend CVS Caremark Call (CVS)
Comtex SmarTrend(R) - Wed Dec 31, 11:17AM CST
SmarTrend identified an Uptrend for CVS Caremark (NYSE:CVS) on July 24th, 2014 at $78.59. In approximately 5 months, CVS Caremark has returned 24.12% as of today's recent price of $97.54.
CVS: 95.10 (-1.21)

5 Prescriptions for $1 Billion in Cost Cuts at Walgreen
Bruce Japsen, The Motley Fool - Motley Fool - Mon Dec 29, 12:31PM CST
On Wednesday,  Walgreen Company   will complete its acquisition of major global drug retailer Alliance Boots and make its debut as a new holding company, Walgreens Boots Alliance, on the Nasdaq market under the ticker symbol WBA. Walgreen CEO...
CVS: 95.10 (-1.21), WAG: 76.05 (-0.49)

CVS Caremark (CVS) Approaches New Downside Target of $97.56
Comtex SmarTrend(R) - Mon Dec 29, 11:40AM CST
CVS Caremark (NYSE:CVS) has opened bearishly below the pivot of $98.26 today and has reached the first level of support at $97.91. Investors may be interested in a cross of the next downside pivot targets of $97.56 and $96.86.
CVS: 95.10 (-1.21)

Pharma Stocks Could Be in Deep Trouble in 2015. Here's Why.
George Budwell, The Motley Fool - Motley Fool - Sun Dec 28, 12:05PM CST
Source: Flickr via user Derek Gavey. Pharmaceutical companies have had some of the best-performing stocks over the last couple of years thanks to an innovation boom that has produced a host of new game-changing drugs, from Gilead Sciences ' ...
ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), IBB: 306.34 (+2.99), CVS: 95.10 (-1.21), ABBV: 65.89 (+0.45), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)

3 Can't Miss Quotes from Rite Aid Corporation's CEO
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 28, 9:57AM CST
Source: Rite Aid Corp. Rite Aid Corporation   went from stock market darling to dud this past year, but solid fiscal third quarter results suggest that shares could return to their winning ways. Despite operating 23 fewer stores during the...
MCK: 207.20 (-0.38), CVS: 95.10 (-1.21), WAG: 76.05 (-0.49), RAD: 7.63 (+0.11)

Cardinal Health (CAH) Rides High on Accretive Acquisitions - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 26, 10:10AM CST
We are impressed by the fact that Cardinal Health (CAH) is focused on its acquisition-driven strategy and continued investments in key growth businesses.
MCK: 207.20 (-0.38), CAH: 80.51 (-0.22), CVS: 95.10 (-1.21), HSIC: 136.84 (+0.69)

Continued Increase In Sales Earns CVS A Bullish Thesis
Equity Watch - at Seeking Alpha - Thu Dec 25, 2:08AM CST

CVS: 95.10 (-1.21)

Could Express Scripts Holding Company's Gilead Gamble Backfire?
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 24, 12:03PM CST
Source: CVS Health. In case you missed it, the hepatitis C community was turned on its head this past weekend with the approval of a new hepatitis C compound and a major move by a pharmacy-benefits manager to strike a long-term deal with that...
ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), CVS: 95.10 (-1.21), ABBV: 65.89 (+0.45), WAG: 76.05 (-0.49)

CVS Caremark Has Returned 24.7% Since SmarTrend Recommendation (CVS)
Comtex SmarTrend(R) - Wed Dec 24, 9:42AM CST
SmarTrend identified an Uptrend for CVS Caremark (NYSE:CVS) on July 24th, 2014 at $78.59. In approximately 5 months, CVS Caremark has returned 24.69% as of today's recent price of $97.98.
CVS: 95.10 (-1.21)

Update: Walgreen Earnings Put The Green In Walgreen
The Specialist - at Seeking Alpha - Tue Dec 23, 1:39PM CST

CVS: 95.10 (-1.21), WAG: 76.05 (-0.49), RAD: 7.63 (+0.11)

Walgreen Q1 Earnings Top On Strong Prescription Sales
at Investor's Business Daily - Tue Dec 23, 10:50AM CST
A record number of prescriptions helped boost Walgreen 's (WAG) first-quarter results above analyst estimates. On Tuesday, the drugstore chain reported a 12.5% increase in earnings to 81 cents per share. Analysts polled by Thomson Reuters were...
CVS: 95.10 (-1.21), WAG: 76.05 (-0.49), RAD: 7.63 (+0.11)

Today's Market: Moving Higher On Strong Earnings And Pricing Power
Matthew Smith - at Seeking Alpha - Tue Dec 23, 10:48AM CST

SPY: 205.43 (-0.11), HTZ: 25.02 (+0.08), JPM: 62.49 (-0.09), GMCR: 131.97 (-0.43), DIA: 177.94 (+0.06), SNE: 20.56 (+0.09), CVS: 95.10 (-1.21), WAG: 76.05 (-0.49)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking the Code of America's Delivery Addiction

Updated Category News Views 4

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 7

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 8

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 8

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
K-Beauty Takes Front Stage at Target Beauty Studio

Updated Category News Views 5

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 8

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Updated Category News Views 4

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 6

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading

Top 5 Most Recently Viewed Articles

Bellring Brands Achieves Record Stock High Amid Market Optimism

Updated Category News Views 178

Bellring Brands Achieves Record Stock High in Financial Milestone Bellring Brands LLC (BRBR) has made headlines recently as its stock reached an impressive milestone, hitting an all-time high of $62.76. This remarkable increase signals a surge in investor confidence, demonstrated by the stock's substantial 1-year change of 46.23%. The performance of Bellring Brands has...

Continue Reading
Celebrating Dr. Shelley Doumani-Semino's Lifetime Achievement

Updated Category News Views 216

Dr. Shelley Doumani-Semino Earns Pinnacle Lifetime Membership Renowned for her significant contributions to the field of addiction psychiatry, Dr. Shelley Doumani-Semino, MD, LFAPA, has been honored with the designation of Pinnacle Lifetime Member, as highlighted in The Inner Circle. This recognition celebrates her extensive work in addiction psychiatry and psychiatric...

Continue Reading
Arcus Biosciences Plans Conference Call for Q3 Financial Review

Updated Category News Views 40

Conference Call Announcement for Financial Results Arcus Biosciences (NYSE: RCUS), a forward-thinking clinical-stage biopharmaceutical company, has announced plans for a significant conference call. The focus will be on discussing its financial results for the third quarter, as well as updates on its product pipeline, which is crucial for its commitment to provide...

Continue Reading
CareDx Achieves Major Milestone as DOJ Closes Investigation

Updated Category News Views 148

CareDx Gains Confidence as Investigations Conclude Recently, CareDx, Inc. (NASDAQ: CDNA) celebrated a significant victory as BTIG reaffirmed its Buy rating, coupled with an ambitious $40 price target for the company's stocks. This optimistic outlook emerged right after the Department of Justice (DOJ) completed its investigation, finding no evidence of misconduct and...

Continue Reading
Indaptus Therapeutics CEO Engages at 2024 Maxim Summit

Updated Category News Views 93

Indaptus Therapeutics CEO to Speak at 2024 Maxim Healthcare Summit Indaptus Therapeutics, Inc. is set to make waves at the upcoming 2024 Maxim Healthcare Virtual Summit. The company's Chief Executive Officer, Jeffrey A. Meckler, will host a fireside chat during the event, which promises to be filled with insightful discussions about the company’s innovative approaches...

Continue Reading